Evidence map›Paper›PMID 42525247›Full record

ArticleClinical & experimental metastasis2026

CYP4B1 inhibits lung adenocarcinoma metastasis by downregulating slug transcription via Sp1.

Sijia Wang, Yijie Liu, Yuan Yu, Shuwei Ren, Weiwei Lin, Kemeng Qiang, Haishan Huang, Honglei Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sijia WangZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Yijie LiuZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Yuan YuZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Shuwei RenZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Weiwei LinZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Kemeng QiangZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Haishan HuangZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Honglei JinZhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. jinhonglei@wmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer, is characterized by strong metastatic potential and poor survival rates. Here, we identified CYP4B1 as a potential biomarker associated with LUAD progression. Through immunohistochemical analyses, we observed that CYP4B1 expression levels were significantly downregulated in tumors. Clinically, low CYP4B1 expression was correlated with shorter disease-free survival in LUAD patients, but not in those with lung squamous cell carcinoma. Functional experiments, including transwell and soft agar assays, demonstrated that CYP4B1 overexpression suppressed the migration and invasion capabilities of LUAD cells without influencing their proliferation, acting through Sp1-mediated Slug downregulation. These findings establish the CYP4B1/Slug axis as a LUAD-associated regulatory mechanism and highlight its potential as a therapeutic target, underscoring the importance of molecular stratification in precision oncology.

Indexed as

Adenocarcinoma of LungLung NeoplasmsSnail Family Transcription FactorsSp1 Transcription FactorAnimalsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm InvasivenessBiomarkers, TumorSNAI1 protein, humanSnail Family Transcription FactorsSP1 protein, humanSp1 Transcription FactorCYP4B1Lung adenocarcinomaMetastasisSlugSp1

Identifiers

PMID42525247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.